

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
08 February 2018 (08.02.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/026722 A8

(51) International Patent Classification:

A61K 39/395 (2006.01) C07K 16/40 (2006.01)
A61K 45/06 (2006.01)

(21) International Application Number:

PCT/US2017/044714

(22) International Filing Date:

31 July 2017 (31.07.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/369,674	01 August 2016 (01.08.2016)	US
62/419,420	08 November 2016 (08.11.2016)	US
62/478,336	29 March 2017 (29.03.2017)	US

(71) Applicants: **OMEROS CORPORATION** [US/US]; 201 Elliott Avenue West, Seattle, WA 98119 (US). **UNIVERSITY OF LEICESTER** [GB/GB]; University Road, Leicester, LE1 7RH (GB).

(72) Inventors: **CUMMINGS, W., Jason**; 3503 109th Place Northeast #1, Bellevue, WA 98004 (US). **DEMOPU-**


LOS, Gregory, A.; 4845 Forest Avenue SE, Mercer Island, WA 98040 (US). **DUDLER, Thomas**; 13410 NE 36th Street, Bellevue, WA 98005 (US). **SCHWAEBLE, Hans-Wilhelm**; 36 The Green, Mountsorrel LE12 7AF (GB). **TJOELKER, Larry, W.**; 11731 Northeast 145th Street, Kirkland, WA 98034 (US). **WOOD, Christi, L.**; 19409 Broadway Avenue, Snohomish, WA 98296 (US). **YABUKI, Munechisa**; 722 North 88th Street, Seattle, WA 98103 (US).

(74) Agent: **QUINTON, Tineka**; Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: COMPOSITIONS AND METHODS OF INHIBITING MASP-3 FOR THE TREATMENT OF VARIOUS DISEASES AND DISORDERS

FIG. 58

MASP-3 mAbs inhibit the APC *in vivo*

(57) Abstract: The present invention relates to MASP-3 inhibitory antibodies and compositions comprising such antibodies for use in inhibiting the adverse effects of MASP-3 dependent complement activation.

[Continued on next page]

WO 2018/026722 A8

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

27 December 2018 (27.12.2018)

(15) Information about Correction:

see Notice of 27 December 2018 (27.12.2018)